Division of Infectious Diseases

Slides:

Advertisements

Similar presentations

Molecular testing for detection of Mycobacterium tuberculosis San Francisco Department of Public Health Laboratory.

Advertisements

Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.

Agenda Background Current testings Xpert MTB/RIF product PAGE | 1.

` COMPARATIVE ACCURACY OF CARTRIDGE BASED NUCLEIC ACID AMPLIFICATION TEST AND SPUTUM MICROSCOPY FOR DIAGNOSIS OF PULMONARY TUBERCULOSIS IN HIV POSITIVE.

New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.

1 |1 | Implementing HIV and TB Diagnostics in Resource Cape Town, South Africa, September 23 rd, 2014 New diagnostic technologies in development and target.

World Health Organization TB Case Definitions

Nucleic Acid Amplification Test for Tuberculosis

Washington D.C., USA, July 2012www.aids2012.org The value of universal TB screening with GeneXpert MTB/RIF in pre-ART patients in Harare L. Mupfumi.

Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and Rifampin Resistance in HIV Infected & HIV uninfected Pulmonary TB suspects: ACTG.

Moving forward in the diagnosis of infectious diseases in developing countries: a focus on malaria Forum organized by Fondation Mérieux & the Roll Back.

Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.

LABORATORIES and DIAGNOSIS of TUBERCULOSIS Assoc. Prof. Alpaslan Alp Hacettepe University Faculty of Medicine Department of Medical Microbiology.

1 Epidemiology of Pediatric Tuberculosis in the United States, 1993–2006 Surveillance, Epidemiology, and Outbreak Investigations Branch Division of Tuberculosis.

Colorado Department of Public Health and Environment Tuberculosis Prevention and Control Program.

Tuberculosis Research of INA-RESPOND on Drug-resistant

Revision of new diagnostics for TB

Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-

NAAT Is it Time for a New Option in California?. Background CDC 2009 guidelines recommend NAAT for each patient with suspected TB for whom the test result.

Surveillance, Epidemiology, and Outbreak Investigations Branch Division of Tuberculosis Elimination Centers for Disease Control and Prevention (CDC) Epidemiology.

Surveillance, Epidemiology, and Outbreak Investigations Branch Division of Tuberculosis Elimination Centers for Disease Control and Prevention (CDC) Epidemiology.

Dr Justin O’Grady. Zambia is a high burden TB and high HIV setting 44,154 TB cases notified in 2010 – incidence of 462/100,000 pop Approx 48% of pulmonary.

Distribution of MTB among newly diagnosed HIV patients at Malindi District Hospital during July 2012 to June Sheldon kalu 1 1 Malindi District Hospital.

Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.

INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS Identification of Mycobacterium tuberculosis complex in clinical specimens of HIV-infected patients at Instituto.

#AIDS2016 Intensified TB case-finding among PLHIV: diagnostic yield of Xpert MTB/RIF, Determine TB-LAM and liquid culture Fred Semitala,

TB – LABORATORY INVESTIGATIONS by Dr. Zubaidah Abdul Wahab Datin Dr. Ganeswrie Raj 1.

Article review Rapid Molecular Detection of Tuberculosis and Rifampin Resistance [MTB-RIF test] Catharina C. Boehme, M.D., Pamela Nabeta, M.D., Doris Hillemann,

François-Xavier BLANC, MD, PhD Nantes University France

New WHO algorithm to prevent TB deaths in seriously ill patients with HIV Yohhei Hamada TB/HIV and Community Engagement.

CASES OF PLEURAL EFFUSION (n=56)

Addressing the challenges and successes of expediting TB treatment among PLHIV who are seriously ill: experience from Kenya Masini E & Olwande C National.

GeneXpert MTB/RIF assay(n=117)

Participants 18year old+

Field Testing of OMNI-gene TB Sputum Optimizer in Malawi

World Tuberculosis Day 2014

Biosafety Implications of GeneXpert MTB/RIF assay: Experience of the National Tuberculosis Reference Laboratory , Lagos Nwokoye N, Onubogu CC, Nwadike.

LAM assay: overview and practical guidance on its adoption and use

World Tuberculosis Day 2013

Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV- associated pulmonary tuberculosis before antiretroviral therapy:

World Tuberculosis Day 2014

Figure 1. Paradigm for evaluation of those with latent tuberculosis infection (LTBI) based on risk of infection, risk of progression to tuberculosis, and.

California Clinical Laboratory Association

William Burman Denver Public Health Tuberculosis Trials Consortium

Nucleic Acid Amplification Test for Tuberculosis

PAEDIATRIC TUBERCULOSIS MAY STILL BE UNDER DIAGNOSED AND UNDER TREATED

World Tuberculosis Day 2015

Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV- associated pulmonary tuberculosis before antiretroviral therapy:

اهمیت سل در چیست؟ حدود یک سوم جمعیت جهان(2 میلیارد نفر)با میکروب سل آلوده شده اند سالانه 9 میلیون نفر به سل فعال مبتلا می شوند هر ساله 1/5 تا 2 میلیون.

CDC Guidelines for Use of QuantiFERON®-TB Gold Test

Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.

Evidence for use of urinary LAM

Molecular Diagnosis in Resource-Limited Settings Camilla Rodrigues, M

World Tuberculosis Day 2014

Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries Kathrin Zürcher, Marie Ballif, Lukas Fenner, Sonia.

World Tuberculosis Day 2016

World Tuberculosis Day 2014

24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.

Evaluation of a Urine-Based Rapid Molecular Diagnostic Test with Potential to Be Used at Point-of-Care for Pulmonary Tuberculosis Krutarth Patel, Matilde.

Figure 1. Evaluation the sensitivity and specificity value of urine LAM and sputum AFB Procedure using GeneXpert as the Reference (Gold Standard) From:

Goal Objectives Expected Outcomes

Deciphering TB Lab Reports

Characteristics LAM Result Total (%) 95% CI Odds ratio

Using Whole Genome Sequencing Analysis in California

Nanotechnology to improve the diagnosis of tuberculosis in children

TB Screening and Differentiated Service Delivery: State of the Art

The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection O. Opota, J. Mazza-Stalder,

Decade of field experience with TB GeneXpert IAS 2019 Satellite session Mexico, 22 July 2019 By Jean de Dieu IRAGENA Technical Officer Laboratory WHO/AFRO,

Rapid Detection of HIV-1 subtype C Integrase resistance mutations by the Use of High-Resolution Melting Analysis Tendai Washaya BSc, Msc. Pre-PhD Student.

Presentation transcript:

Division of Infectious Diseases Xpert® MTB/RIF Ultra: The Next-Generation Assay for Tuberculosis Diagnosis and Rifampin Resistance Detection Diego P. Peralta, M.D., FACP Assistant Professor Division of Infectious Diseases March 22, 2018 Texas Association for Clinical Laboratory Science

Disclosures No financial disclosures to report.

Objectives At the end of the session, the participant will be able to: Identify the differences between the Xpert® MTB/RIF Ultra assay and its predecessor. Describe the Xpert® MTB/RIF Ultra assay clinical applications. Appraise the evidence to support the use of Xpert® MTB/RIF Ultra assay in tuberculosis diagnosis and Rifampin resistance detection.

Tuberculosis http://www.healthtipsever.com/what-is-tuberculosis/

Epidemiology WHO Estimates 2015 2016 New TB cases reported 10.4 million TB diagnosis 6.1 million (59%) 6.3 million (61%) Deaths attributable to TB 1.8 million 1.3 million Rifampicin resistance 580,000 600,000 Dorman SE et al. Lancet Infect Dis. 2018 Jan;18(1):76-84 WHO. Global Tuberculosis Report 2017.; 2017. doi: WHO/HTM/TB/2017.23.

Epidemiology WHO. Global Tuberculosis Report 2017.; 2017. doi: WHO/HTM/TB/2017.23.

Epidemiology TB is the ninth leading cause of death worldwide TB is the leading cause of death from a single infectious agent, ranking above HIV/AIDS WHO. Global Tuberculosis Report 2017.; 2017. doi: WHO/HTM/TB/2017.23.

Reported TB Cases United States, 1982-2016* CDC. National Tuberculosis Surveillance System 2016 * As of June 21, 2017

TB Case Rates,* United States, 2016 * Cases per 100,000; as of June 21, 2017. DC, District of Columbia; NYC, New York City (excluded from New York state) CDC. National Tuberculosis Surveillance System 2016

TB Morbidity United States, 2011–2016 * Cases per 100,000 population; as of June 21, 2017. CDC. National Tuberculosis Surveillance System 2016

WHO: The End TB Strategy WHO aims by 2035: 90% reduction in TB incidence 95% reduction in TB mortality WHO. Global Tuberculosis Report 2017.; 2017. doi: WHO/HTM/TB/2017.23.

Diagnosis Gold standard Smear microscopy is insensitive Culture and drug susceptibility Smear microscopy is insensitive Culture takes too long to be clinically useful For TB diagnosis, highly sensitive, rapid, and accessible diagnostics are needed WHO. Global Tuberculosis Report 2017.; 2017. doi: WHO/HTM/TB/2017.23.

Diagnosis Several assays are endorsed by the WHO: Line Probe Assays Gen-Probe Mycobacterium Tuberculosis Direct Urine lateral flow lipoarabinomannan (LF-LAM) Loop-mediated isothermal amplification (TB-LAMP) Xpert® MTB/RIF assay WHO. Global Tuberculosis Report 2017.; 2017. doi: WHO/HTM/TB/2017.23.

Xpert® MTB/RIF Assay Automated in vitro test Uses real-time PCR Qualitative detection of MTB and RIF resistance Primers amplify a portion of rpoB gene containing the 81 base pair core region Probes differentiate the conserved wild-type sequence and mutations in the core region associated with RIF resistance GeneXpert Technology. Cepheid Website http://www.cepheid.com/us/cepheid-solutions/clinical-ivd-tests/critical-infectious-diseases/xpert-mtb-rif/309?view=product

Xpert® MTB/RIF Assay GeneXpert Technology. Cepheid Website http://www.cepheid.com/us/cepheid-solutions/clinical-ivd-tests/critical-infectious-diseases/xpert-mtb-rif/309?view=product

History 2010 WHO endorsed the Xpert® MTB/RIF assay for initial diagnostic testing of individuals suspected of MDR-TB or HIV-associated TB 2013 FDA permitted marketing of the Xpert® MTB/RIF assay 2014 WHO expanded recommendation for use in all patients (including also extra-pulmonary TB) MMWR Morb Mortal Wkly Rep. 2013 Oct 18;62(41):821-7. WHO. Global Tuberculosis Report 2017.; 2017. doi: WHO/HTM/TB/2017.23.

Going Ultra: Xpert® MTB/RIF Ultra Xpert® MTB/RIF has limitations March 2017 WHO recommended: Replacement of Xpert® MTB/RIF by Xpert® MTB/RIF Ultra Going Ultra: Xpert® MTB/RIF Ultra WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTF/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization; 2017 (WHO/HTM/TB/2017.04). Licence: CC BY-NCSA 3.0 IGO.

Differences between Xpert and Ultra Xpert® MTB/RIF Xpert® MTB/RIF Ultra Two multi-copy amplification targets (IS6110 and IS1081) Fully nested nucleic acid amplification More rapid thermal cycling Improved fluidics and enzymes DNA PCR reaction chamber 25 µl 50 µl Limit of detection 114 bacterial CFU/mL 16 bacterial CFU/mL Semi-quantitative categories High, medium, low and very low High, medium, low, very low, and trace (trace call) 1–log improvement in the lower limit of detection RIF resistance detection Real-time PCR Melting temperature-based analysis Improved differentiation of certain silent RIF mutations and detection of RIF resistance in mixed infections and paucibacillary specimens WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTF/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization; 2017 (WHO/HTM/TB/2017.04). Licence: CC BY-NCSA 3.0 IGO.

Xpert® MTB/RIF Ultra Pros: Higher sensitivity Cons: Lower specificity Increase diagnosis of paucibacillary forms of TB Childhood TB HIV-associated TB Extrapulmonary TB Cons: Lower specificity Previously treated/history of TB High-incidence countries WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTF/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization; 2017 (WHO/HTM/TB/2017.04). Licence: CC BY-NCSA 3.0 IGO. Arch Bronconeumol. 2017 Dec;53(12):665-666. doi: 10.1016/j.arbres.2017.05.023. Epub 2017 Jul 10.

Xpert® MTB/RIF Ultra Lower specificity represents Possible explanation Higher proportion of false positive results Empiric treatment and possibly overtreatment that might undermine clinical effect Possible explanation Detection of DNA from non-viable M. tuberculosis Prolonged excretion of M. tuberculosis DNA form TB lesions after treatment M. tuberculosis DNA from dead bacilli has high stability (DNA can be detected in millennia-old human remains) WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTF/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization; 2017 (WHO/HTM/TB/2017.04). Licence: CC BY-NCSA 3.0 IGO. Arch Bronconeumol. 2017 Dec;53(12):665-666. doi: 10.1016/j.arbres.2017.05.023. Epub 2017 Jul 10.

Study Justification Limitations of Xpert MTB/RIF assay Imperfect sensitivity for paucibacillary disease (HIV, early disease, children, etc) Imperfect sensitivity for RIF-resistance detection in case of heteroresistance Imperfect specificity for RIF-resistance detection due to silent mutation detection Cross-reactivity with some nontuberculous mycobacteria (NTM) Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf. CROI 2017. Rodwell T. A Multicenter Diagnostic Accuracy Study of the Xpert Ultra for Tuberculosis Diagnosis. http://www.croiwebcasts.org/console/player/33479?mediaType=audio&

Study Design: Index test: Comparator: Reference standard: Blinded, multicenter, prospective non-inferiority study. Index test: Xpert® MTB/RIF Ultra Comparator: Xpert ® MTB/RIF Reference standard: Culture, drug susceptibility, sequencing Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Primary Outcomes: MTB detection RIF detection ∆ Sensitivity: among smear-negative/culture-positive patients ∆ Specificity RIF detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Secondary Outcomes Estimates of accuracy for MTB detection Overall/pooled By smear-status By HIV status By TB history and time since treatment completion By site On secondary study samples Root-cause analysis of discordant results between Ultra and culture Analyses reclassifying the ‘trace’ call Analysis of NTMs Analysis of semi-quantitative results Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Sites Ten sites in eight countries Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Sample Computed sample: Sample: 1143 1520 eligible for analysis Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Flow at Enrollment Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Non-inferiority Margins for Comparison between Xpert and Ultra Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Main Results

Demographic and Clinical Characteristics of Sample Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Sensitivity and Specificity of Xpert and Ultra for MTB Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Sensitivity and Specificity of Xpert and Ultra for MTB Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Sensitivity and Specificity of Xpert and Ultra for MTB Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Sensitivity and Specificity of Xpert and Ultra for RIF Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Sensitivity and Specificity of Xpert and Ultra for RIF Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Sensitivity and Specificity of Xpert and Ultra for RIF Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Specificity Overall and by Treatment History Status Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Specificity Overall and by Treatment History Status Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Specificity Overall and by Treatment History Status Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Specificity Overall and by Treatment History Status Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Non-inferiority Analysis for MTB Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Non-inferiority Analysis for MTB Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Non-inferiority Analysis for MTB Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Non-inferiority Analysis for MTB Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Non-inferiority Analysis for MTB Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Non-inferiority Analysis for MTB Detection +17% -3.2% Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Non-inferiority Analysis for RIF Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Non-inferiority Analysis for RIF Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Non-inferiority Analysis for RIF Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Non-inferiority Analysis for RIF Detection Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Non-inferiority Analysis for RIF Detection -0.6% +0.3% Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Primary Analysis Findings MTB detection Ultra shows improved sensitivity but reduced specificity Performance for RIF detection is very similar Non-inferiority met for specificity, but missed by a small margin for sensitivity Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Primary Analysis Findings MTB detection Ultra shows improved sensitivity but reduced specificity Performance for RIF detection is very similar Non-inferiority met for specificity, but missed by a small margin for sensitivity Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Primary Analysis Findings MTB detection Ultra shows improved sensitivity but reduced specificity Performance for RIF detection is very similar Non-inferiority met for specificity, but missed by a small margin for sensitivity Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Primary Analysis Findings MTB detection Ultra shows improved sensitivity but reduced specificity Performance for RIF detection is very similar Non-inferiority met for specificity, but missed by a small margin for sensitivity Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Secondary Analysis Findings Specificity of both Xpert and Ultra are affected by TB history Stronger for Ultra and for recent history Trade-off of higher sensitivity is lower specificity of Ultra “trace-calls” Reclassification of “trace-calls” as ‘TB-negative’ mitigates specificity losses while maintaining some of the sensitivity gains To be considered for all patients or for patients with TB history Re-testing of “trace-call” results with a second Ultra is another possibility to mitigate specificity losses leading to similar results as reclassification state above Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Other Secondary Analysis Findings Analyses by site: Expected variability of sensitivity-estimates between sites due to small sample Specificity-estimates broadly consistent Root cause analysis: FPs on sample 1 mainly due to non-viable bacilli prior TB Lower specificity-estimates for samples 2 and 3 versus sample 1 is likely due cross-contamination Cross-contamination was due to procedures that were performed in certain sites (i.e., beads homogenization) Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Conclusions Ultra offers opportunities for increased TB detection Ultra has increased sensitivity for TB detection including patients with paucibacillary disease Ultra has decreased specificity in patients with prior history of TB Ultra implementation needs to be considered carefully due to reduced specificity Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Additional Data Published with Main Study: CE-mark, Extra-pulmonary TB, Elimination in non-HBDC, and Pediatric Cases

CE-mark Data Data provided by Cepheid MTB detection: Sensitivity: Smear-positive: 99.5% (95%CI 98.3, 99.9) Smear-negative: 73.4% (95%CI 67.7, 78.4) Specificity: Overall: 95.5% (95%CI 94.2, 96.6) RIF resistance detection: Sensitivity: 96.2% (95%CI 91.5-98.4) Specificity: 96.3% (95%CI 93.7-97.9) Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Extra-pulmonary TB TB meningitis Sensitivity: Conclusion: Ultra: 95% Xpert 45% Culture 45% Conclusion: Ultra detected significantly more TB meningitis than either Xpert or culture Adequate CSF testing volume is critical Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Pediatric Study South Africa Culture and Ultra Sensitivity: 75.7% Specificity: 96.5% HIV-infected Sensitivity: 70.6% Specificity: 98.2% HIV-uninfected Sensitivity: 77.2% Specificity: 96.1% Conclusion: Ultra provides rapid detection of MTB from a single induced sputum in most children with culture confirmed TB Ultra may detect an additional group of children with TB, who are not detected by culture Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Evaluation of the Ultra Assay in a Pediatric TB Study from Tanzania Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Evaluation of the Ultra Assay in a Pediatric TB Study from Tanzania Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Evaluation of the Ultra Assay in a Pediatric TB Study from Tanzania Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

Summary of Findings Shows a significant increase of sensitivity for Ultra in TB meningitis Suggests an increase in sensitivity in paucibacillary disease (i.e., children and active case finding in asylum seekers) Sensitivity increase is attributable to Ultra “trace call” Foundation for Innovative New Diagnostics (FIND). Report for WHO: A Multicentre Non-Inferiority Diagnostic Accuracy Study of the Ultra Assay Compared to Xpert MTB/RIF Assay. 2017. https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf.

WHO Position Regarding Xpert® MTB/RIF Ultra Ultra assay is non-inferior to Xpert assay for the diagnosis of MTB and detection of RIF resistance Ultra can be used as an alternative to Xpert in all settings Ultra can be used as the initial diagnostic test for all adults and children with signs and symptoms of TB Ultra can be used in the testing of selected extra pulmonary specimens (CSF, lymph nodes and tissue specimens) Interpretation of Ultra is similar to Xpert except for “trace call” WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTF/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization; 2017 (WHO/HTM/TB/2017.04). Licence: CC BY-NCSA 3.0 IGO.

Recent Published Studies Using the Xpert® MTB/RIF Ultra Assay

Lancet Infect Dis. 2018 Jan;18(1):76-84. doi: 10 Lancet Infect Dis. 2018 Jan;18(1):76-84. doi: 10.1016/S1473-3099(17)30691-6. Epub 2017 Nov 30.

Lancet Infect Dis. 2018 Jan;18(1):76-84. doi: 10 Lancet Infect Dis. 2018 Jan;18(1):76-84. doi: 10.1016/S1473-3099(17)30691-6. Epub 2017 Nov 30.

Lancet Infect Dis. 2018 Jan;18(1):68-75. doi: 10 Lancet Infect Dis. 2018 Jan;18(1):68-75. doi: 10.1016/S1473-3099(17)30474-7. Epub 2017 Sep 14.

Lancet Infect Dis. 2018 Jan;18(1):68-75. doi: 10 Lancet Infect Dis. 2018 Jan;18(1):68-75. doi: 10.1016/S1473-3099(17)30474-7. Epub 2017 Sep 14.

PLoS Med. 2017 Dec 14;14(12):e1002472. doi: 10. 1371/journal. pmed PLoS Med. 2017 Dec 14;14(12):e1002472. doi: 10.1371/journal.pmed.1002472. eCollection 2017 Dec.

PLoS Med. 2017 Dec 14;14(12):e1002472. doi: 10. 1371/journal. pmed PLoS Med. 2017 Dec 14;14(12):e1002472. doi: 10.1371/journal.pmed.1002472. eCollection 2017 Dec.

Pediatr Infect Dis J. 2018 Feb 22. doi: 10. 1097/INF. 0000000000001960 Pediatr Infect Dis J. 2018 Feb 22. doi: 10.1097/INF.0000000000001960. [Epub ahead of print]

Pediatr Infect Dis J. 2018 Feb 22. doi: 10. 1097/INF. 0000000000001960 Pediatr Infect Dis J. 2018 Feb 22. doi: 10.1097/INF.0000000000001960. [Epub ahead of print]

Division of Infectious Diseases Xpert® MTB/RIF Ultra: The Next-Generation Assay for Tuberculosis Diagnosis and Rifampin Resistance Detection Diego P. Peralta, M.D., FACP Assistant Professor Division of Infectious Diseases March 22, 2018 Texas Association for Clinical Laboratory Science